Page 31 - Sohini Das

Anti-obesity drug market on steady growth path in India, shows data

The anti-obesity drugs' market had a sluggish growth till 2021, says Sheetal Sapale, vice-president, commercial, Pharmarack, a market research firm

JB Pharma CEO attributes 3.5% of company's growth to new introductions

Chopra said company grows at 16% compared to Indian pharma market growth of 8%

Tax implications likely to influence Hyundai's decision to list Indian arm

Hyundai Motor is exploring an initial public offering (IPO) of its Indian unit to raise around $3 bn (at a valuation of up to $30 bn), according to sources

Lupin Q3 results: Net jumps 300% to Rs 613 cr on back of record sales

Nilesh Gupta, MD, Lupin Limited said, "We delivered our highest quarterly sales to date, crossed the Rs 5,000 crore mark for the first time, driven by strong growth across geographies."

Rooftop solar charges up electric vehicle boom in India's smaller cities

Rajasthan, Gujarat, and Kerala see more users

Standardisation a critical pulse for better govt health care access

The Insurance Regulatory and Development Authority of India has also asked companies to modify products that contain limitations for Ayush treatments and ensure compliance

JB Pharma Q3 results: Profit after tax rises 26% on strong India biz

The domestic formulation business has been the growth driver during the quarter, clocking a 14 per cent Y-o-Y growth to Rs 462 crore

Mukesh Ambani to Gautam Adani: Big guns firing on the capex front

In the Interim Budget speech on Thursday, Union Finance Minister Nirmala Sitharaman said "private investments are happening at scale"

Falling biotech funding may be a bitter pill to swallow for CDMOs

Indian CDMOs are focusing on big biotech clients, and going forward, they believe the funding issues will not last long

Tata Motors Q3 results: Net profit jumps 137% to Rs 7,025, revenue up 25%

The company remains upbeat on all three auto businesses and expects to do better in Q4

PLI will be among biggest sources of funds for EV biz next yr: Tata Motors

PLI benefits would range from 13-18% of revenue for vehicles approved by the government for the scheme

Interim Budget: Over 3 mn ASHA, anganwadi workers now in Ayushman Bharat

Push to include cervical cancer vaccination in Universal Immunisation Programme and set up more medical colleges

Sun Pharma Q3 results: Net profit up 16.5% at Rs 2,524 cr on US, India biz

Bloomberg analysts' estimates had pegged the revenue at Rs 12,336 crore and PAT at Rs 2,470 crore

Incumbents strike back: How will electric 2W game play out for Ola, others?

There is indeed a lot of the race left. Electric, for all the hype, is just about 15 per cent of the scooter market. So, what is on the cards?

Breather for consumers as drug prices likely to remain same this year

In previous two years, hikes were in the range of 10-12%

Battle shifts to new class of drugs in diabetes treatment in India

Glenmark Pharmaceuticals launched a biosimilar version of liraglutide earlier this month, after getting the nod from the Drugs Controller General of India (DCGI)

Cipla board rejig: Samina Hamied to step down from executive role

Balram Bhargava appointed as independent director on board

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

Bajaj Auto Q3 net profit up 38% at Rs 2,032 cr on good domestic biz

No.3 in electric 2-wheeler market riding on Chetak, clocks 10K units-pm volumes

Aster DM shareholders approve separation of firm's India, GCC businesses

Aster DM earlier announced plans to separate its India and Gulf businesses in a deal valued at $1 billion